Drug approved by the FDA
for the treatment of Duchenne.
CureDuchenne was an early funder.
CureDuchenne funded research projects
have advanced to human clinical trials
Our lives were changed forever…
“We didn’t know anything about Duchenne and felt isolated that there was no one we could turn to… CureDuchenne has hosted several workshops that have been invaluable in providing knowledge on the care, treatment and future of our son, but, even more importantly, has enabled us to spend time with other Duchenne families…”
Duchenne is a devastating muscle disease.
It’s the most common and severe form of muscular dystrophy. Those affected with Duchenne lose their ability to walk, feed themselves, breath independently and succumb to heart failure. But there’s hope through new pharmacological and gene-based therapies. You can help make a difference.
Data show for the first time a systemic therapeutic effect in DMD dogs using a rAAV2/8 micro-dystrophin gene therapy approach without immunosuppressive treatment CAMBRIDGE, Mass., July 27, 2017 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today […]
CURE DUCHENNE NEWS
— Anaheim Ducks Captain Ryan Getzlaf and Wife Paige Getzlaf Continue their Support of CureDuchenne – Newport Beach, CA (Sept. 20, 2017) – The 7th Annual Getzlaf Golf Shootout benefiting CureDuchenne raised more than $546,000 to help find a cure for Duchenne muscular dystrophy. Hosted by Anaheim Ducks Captain Ryan Getzlaf and his wife Paige, […]